Semagacestat (LY450139)
(Synonyms: 司马西特,LY-450139, LY 450139,Semagacestat ) 目录号 : GC12096A pan γ-secretase inhibitor
Cas No.:425386-60-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | |
Cell lines |
H4 human glioma cells stably overexpressing human wild-type APP695 |
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
Reaction Conditions |
24 h; 10 μM |
Applications |
Using H4 cells stably overexpressing human wild-type APP, LY450139 reduced the secretion of Aβ42, Aβ40, and Aβ38 in 96-well-cultured media and increased β-CTF in cell lysates as expected, although this increase was unexpectedly attenuated at high concentrations. The biphasic β-CTF response to LY450139 was also found in Western blot analysis of six-well-cultured cells using two anti-bodies, 82E1 and 6E10, which recognize the N-terminal region of Aβ. |
Animal experiment: | |
Animal models |
Female Tg2576 mice |
Dosage form |
3 mg/kg, oral taken. |
Applications |
To determine the sites of β-CTF accumulation in response to LY450139, immunofluorescence of anti-human Aβ/β-CTF N-terminal-specific antibody (82E1) was applied to hippocampal slices from Tg2576 mice. Three-month-old Tg2576 mice were administered 3 mg/kg LY450139 for 8 d, with the brain fixed 3 h after the last administration. When immunofluorescence intensities in these regions were normalized with that in the CA3 stratum pyramidale of the same slice, LY450139-treated mice showed significantly higher relative immunoreactivity compared with the vehicle-treated mice. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Mitani Y, Yarimizu J, Saita K, et al. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice[J]. The Journal of Neuroscience, 2012, 32(6): 2037-2050. |
Semagacestat (also known as LY450139), [(2S)-2-hydroxy-N-((2S)-1-((1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1ylamino)-1-oxopropan-2-yl)-3-methylbutanamide] is an azepine class γ-secretase, which is currently being investigated as a potential disease-modifying agent for the treatment of Alzheimer’s disease (AD). It reduces the rate of formation of amyloid-β (Aβ), a major component of the neuritic plaque in the brains of AD patients, in human subjects and animal models including mice, beagle dogs and guinea pigs. According to previous studies, semagacestat slows the accumulation of Aβ in the brains of transgenic mice overexpressing mutant human amyloid precursor protein V717F (PDAPP mice) and exhibits a dose-dependent decrease of plasma in AD patients.
Reference
[1].Ping Yi, Chad Hadden, Palaniappan Kulanthaivel, Nathan Calvert, William Annes, Thomas Brown, Robert J. Barbuch, Archana Chaudhary, Mosun A. Ayan-Oshodi, and Barbara J. Ring. Disposition and metabolism of semagacestat, a γ-secretase inhibitor, in humans. Drug Metabolism and Disposition 2010; 38(4): 554-565
Cas No. | 425386-60-3 | SDF | |
别名 | 司马西特,LY-450139, LY 450139,Semagacestat | ||
化学名 | (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide | ||
Canonical SMILES | CC(C)C(C(=O)NC(C)C(=O)NC1C2=CC=CC=C2CCN(C1=O)C)O | ||
分子式 | C19H27N3O4 | 分子量 | 361.44 |
溶解度 | ≥ 18.05mg/mL in DMSO, ≥ 40.3 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.7667 mL | 13.8336 mL | 27.6671 mL |
5 mM | 0.5533 mL | 2.7667 mL | 5.5334 mL |
10 mM | 0.2767 mL | 1.3834 mL | 2.7667 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。